Sensata Technologies Holding plc (ST) earnings date, results and what the price requires
NYSE · SEC CIK 0001477294 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $990.6M | $102.1M | $0.70 | Filing |
| Mar 31, 2026 | Apr 28, 2026 | $934.8M | $87.1M | $0.59 | Filing |
| Dec 31, 2025 | Feb 19, 2026 | $917.8M | $63.2M | $0.45 | Filing |
| Sep 30, 2025 | Oct 28, 2025 | $932.0M | $-162.5M | $-1.12 | Filing |
| Jun 30, 2025 | Jul 29, 2025 | $943.4M | $60.7M | $0.41 | Filing |
| Mar 31, 2025 | May 8, 2025 | $911.3M | $69.9M | $0.47 | Filing |
| Dec 31, 2024 | Feb 11, 2025 | $907.7M | $5.8M | $0.05 | Filing |
| Sep 30, 2024 | Nov 4, 2024 | $982.8M | $-25.0M | $-0.17 | Filing |
What would Sensata Technologies Holding plc have to report for its valuation to change?
At $40.58, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 41.1% a year, to $3.47. On that path the next quarter needs diluted EPS near $-1.58, against $-1.12 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 41.1% | 41.1% |
| EPS needed in final year | $3.47 | $3.47 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ST goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.